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Disintegration time is the key critical quality attribute for a tablet classed as an orally Disintegrating 
tablet (oDt). the currently accepted in vitro testing regimen for oDts is the standard United States 
pharmacopeia (USp) test for disintegration of immediate release tablets, which requires a large volume 
along with repeated submergence of the dosage form within the disintegration medium. the aim of this 
study was to develop an in vivo relevant oDt disintegration test that mimicked the environment of the 
oral cavity, including lower volume of disintegration medium, with relevant temperature and humidity 
that represent the conditions of the mouth. the results showed that the newly developed Aston test 
was able to differentiate between different ODTs with small disintegration time windows, as well as 
between immediate release tablets and oDts. the Aston test provided higher correlations between 
ODT properties and disintegration time compared to the USP test method and most significantly, 
resulted in a linear in vitro/in vivo correlation (iViVc) (R2 value of 0.98) compared with a “hockey stick” 
profile of the USP test. This study therefore concluded that the newly developed Aston test is an 
accurate, repeatable, relevant and robust test method for assessing oDt disintegration time which will 
provide the pharmaceutical industry and regulatory authorities across the world with a pragmatic oDt 
testing regime.
Orally disintegrating tablets (ODT) are a solid dosage form that disintegrate rapidly upon contact with saliva in 
the oral cavity. Among the different characterisation methods, disintegration time is one of the most essential 
attributes to ensure that the ODT disintegrates within the recommended US Food and Drug Agency (FDA) time 
of 30 seconds or European Pharmacopoeia time of 3 minutes1.
The currently recommended ODT disintegration test is the United States Pharmacopeia (USP) standard test 
method used for immediate release solid oral dosage forms, as shown in Fig. 1. This method consists of a basket 
rack attached to a rod which oscillates vertically within a beaker filled within approximately 800 ml disintegration 
medium, which is placed beneath the basket assembly and kept at 37 °C. The basket is immersed in the disinte-
gration medium at the frequency of 29–32 cycles per minute through a distance of approximately 53 mm to allow 
tablet disintegration to take place. The basket is made up of six disintegration vessels with a wire mesh at the 
bottom (with hole diameters of 1.8–2.2 mm), and disintegration time is measured once all fragments of the oral 
dosage form have passed through the wire mesh2.
However, under in vivo conditions, an ODT would be placed on the tongue of the patient and then subse-
quently disperse/disintegrate through interaction with the saliva present within the oral cavity. As the tablet is 
placed within the mouth, and the mouth closed; there would be interactions between the ODT and the upper 
palate in a controlled temperature of around 37 °C3, and relative humidity of around 90–95%4. These condi-
tions would aid in the disintegration of the ODT, as the high humidity and temperature would promote further 
moisture uptake into the tablet and the pressing of the tablet against upper palate would further aid in tablet 
breakdown.
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Having considered the in vivo conditions, it is clear that the current recommended USP disintegration test 
method does not bare resemblance to the in vivo conditions. The standard test uses a large volume of disintegra-
tion medium, and the dosage form disintegrates within the oscillating vessel, which simulates the disintegration 
of a conventional tablet that is swallowed with water and disintegrates within the gastrointestinal (GI) tract. Also, 
the time taken for disintegration is measured when the last fragment of the tablet has passed through the wire 
mesh at the bottom of the vessel, which does not necessarily relate to the time taken for the ODT to disintegrate 
within the oral cavity and is subsequently ready to swallow.
The USP “Guidance for Industry: Orally Disintegrating Tablets” has stipulated the need for an alternative test 
for measuring the disintegration time of ODT which bears closer resemblance with in vivo conditions2. Previous 
efforts have been made at conducting an in vivo relevant/correlating test, with methods ranging from the fabri-
cation of tailored equipment5–8, to improvised methods that were developed using currently available lab equip-
ment9–16. However, these different tests suffer from various limitations including absence of controlled conditions 
such as temperature and humidity as well as limited data for demonstrating in vitro/in vivo correlation (IVIVC).
The aim of the study was to develop an in vivo relevant ODT disintegration test method capable of distinguish-
ing marginal differences in the disintegration time of ODTs. This study was designed to develop and conceptu-
alise a new ODT disintegration test which was not only representative of in vivo conditions, but also correlated 
with in vivo results. The results from the final design were compared to an in vivo ODT disintegration time study.
Materials and Methods
This study was split in to two stages: 1. Testing of the newly developed Aston disintegration tester (Aston test) and 
comparing results from tablet properties to the standard USP test method; 2. An in vivo study to determine the 
correlation of in vivo results for comparison between Aston test and the standard USP method.
Materials. Nurofen Meltlets (A marketed ibuprofen 200 mg ODT) and standard immediate release paraceta-
mol tablets were obtained from Reckitt Benckiser (Slough, UK) and Wockhardt (Wrexham, UK) respectively.
Materials for placebo ODT preparation included D-mannitol (Sigma-Aldrich, UK), Microcrystalline Cellulose 
(MCC) (Avicel PH102, FMC Biopolymer, USA), Partially Pregelatinised Maize Starch (Starch 1500®, Colorcon 
Inc., USA), crospovidone (Kollidon CL, BASF, Germany), Pearlitol Flash (Roquette, France), sodium stearyl 
fumarate (Alubra, FMC Biopolymer, USA) and magnesium stearate (Fischer Scientific, UK). Hydroxypropyl 
methylcellulose (HPMC) (METHOCEL™ K100M, provided by Colorcon Inc., UK) was used to manufacture 
hydrophilic matrix tablets.
Tablet preparation. The placebo ODTs manufactured in this study were composed of 60% w/w D-mannitol, 35% 
w/w MCC, 4% w/w crospovidone as the main tablet excipients and 1% w/w magnesium stearate as a lubricant. 
All excipients, except magnesium stearate were blended for 10 mins using a cube blender to achieve a uniform 
powder blend, and then magnesium stearate added and mixed for a further minute. Individual 500 mg portions 
of powder were weighed and compressed using a Specac semi-automatic hydraulic press (Slough, UK) equipped 
with 13 mm flat faced dies. Four compression forces ranging from 75 to 300 MPa were used to more accurately 
evaluate the sensitivity of the disintegration test.
Extended release matrix tablets were composed of 40% w/w HPMC, 40% w/w MCC, 19% w/w D-mannitol 
and 1% w/w magnesium stearate. All the excipients were blended as above. The powders were individually 
Figure 1. A diagram illustrating a typical set up for the standard USP disintegration test for solid oral dosage 
forms that is also recommended for ODT disintegration testing. It shows how the basket would typically by 
placed within the beaker/water bath, and how the dissolution vessels are arranged within the basket.
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weighed to 500 mg and tableted using the Specac semi-automatic hydraulic press (Slough, UK), with the same 
13 mm flat-faced dies as above, followed by compression at 225 MPa.
Validation of disintegration time using Aston test. Two commercially available tablets, an ODT formulation, 
Nurofen Meltlet and a standard release paracetamol were used as model products. Five sets of placebo tablets 
were manufactured to test the time sensitivity within the Aston test; four ODTs compacted at different compres-
sion forces, to give varying hardness and disintegration time profiles, and an extended release matrix tablet, to 
give a control that should not disintegrate within the Aston/USP test.
Aston disintegration test. The newly developed Aston test was fabricated according to the drawing illustrated 
in Fig. 2, which was designed to mimic conditions encountered in the oral cavity. The test housing was placed 
on top of a hot plate, set to an optimised temperature to achieve 37 ± 1 °C within the compartment, similar to in 
vivo conditions3. The test housing contained potassium chloride which was used to form a saturated salt solution 
to provide relative humidity of approximately 93 ± 3% RH in the enclosed container, similar to those conditions 
encountered in the oral cavity17. The disintegration bed was a slightly flattened silicone pipe with 4 mm holes to 
allow water or simulated saliva to flow over the surface of the pipe. This flow of media would interact with the 
tablet and lead to subsequent disintegration within the simulated in vivo conditions. The flow rate of simulated 
saliva was set at 10 ml/min to form a thin film of liquid over the silicone pipe.
The disintegration compartment was placed under the probe of a texture analyser (Brookfield Engineering’s 
CT3 Texture Analyser, Harlow, UK), set at speed of 2 mm/s. Once the tablet came into contact with the disinte-
gration bed, the probe was set to apply a fixed 50 g weight for a set amount of time12,13. A plot of distance vs time 
was then generated from which disintegration time was calculated. The test was repeated on eight tablets and data 
was presented as mean ± standard deviation (SD).
USP disintegration test. The standard USP disintegration method was also used to assess disintegration time of 
the tablets to allow a comparison to the Aston test18. A Copley ZT41 disintegration apparatus (Nottingham, UK) 
was used, with a single tablet being tested at one time for accuracy. Each tablet was placed in the vessel (without 
a disk) and oscillated at 30 cycles per minute. A dissolution medium of 800 ml distilled water was maintained at 
37 °C, and disintegration time measured when all of the fragments of tablet had passed through the mesh at the 
bottom of the vessel. All readings were taken in triplicate and represented as mean ± SD.
Hardness. Tablet hardness was measured using a Copley TBF 100 Hardness tester (Nottingham, UK). Tensile 
strength (σ) was then calculated using the equation:
σ
pi
=
H
D T
2
(1)
where H is the hardness, D is the diameter and T is the tablet thickness. All readings were taken in triplicate and 
displayed as mean ± SD.
Figure 2. A schematic diagram showing the proposed design of the disintegration tester specific for ODTs, 
comprising of conditions representative of the oral cavity, including temperature/humidity, disintegration 
medium flow rate and applied pressure on the tablet. An area for collection of the disintegrating fragments from 
the tablet could also be added to assess drug leakage/absorption in the mouth.
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Porosity. Porosity of the tablets was assessed using a Quantachrome Helium Multipycnometer (Florida, USA). 
Diameter and thickness of the ODTs were measured using a digital calliper, and the weight of individual tablets 
was determined using an electronic balance. The bulk volume (VB) and bulk density (ρbulk) of the tablets were then 
calculated using the following equations:
pi
=V R
T (2)B
2
ρ = Tablet weight
V (3)bulk B
The true volume (Vt) of the tablet was calculated using the pycnometer, which applies the theory of gas dis-
placement allowing the porous nature of the tablet to be assessed. The true volume was calculated using the 
equation:
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where VC is the volume of the sample cell, Vr is the volume of the reference cell, P1 and P2 are the atmospheric 
pressure and pressure change during the measurement respectively. The true volume was then used to calculate 
true density in the equation:
ρ = Tablet weight
V (5)true t
The final step to calculate porosity (ε) of the ODT used the following equation:
ε
ρ
ρ
= −1
(6)
bulk
true
In Vivo/In Vitro correlation (iViVc). In vivo disintegration time assessment. In vivo disintegration time 
was investigated using nine different tablets across 35 healthy human volunteers. The study design is detailed 
below.
Study design. The study was subject to ethics approval from Aston University Ethics Committee and gained a 
favourable opinion letter for commencement of the study based on the Research Protocol, Patient Information 
Sheet and Patient Consent form. The lead investigator, Jasdip Koner, was also certified in Good Clinical Practice 
through the National Health Service (UK). The study was performed in accordance with the relevant guidelines 
and informed consent was obtained from all participants.
The study was designed as a single blind study whereby participants were not aware of the tablet type they 
were taking. Each participant was assigned a participant number according to their chosen seat in the study room, 
which was used by the researchers to assign which tablets were taken. Participants were required to take a total of 
six tablets per scheduled study, the participant was not privy to formulation composition. Participants followed 
a set of instructions laid out by the research team. The tablets were taken in the defined order set out by the 
researchers, and times recorded from when the tablet entered the oral cavity to when the participant felt the tablet 
had disintegrated. Participants were briefed on when the endpoint of disintegration should be/feel like. Prior to 
taking the tablet, participants had to rinse the oral cavity, as well as rinsing at the end of each tablet disintegration 
and before the start of each test. A wait time of 1–2 minutes was advised to allow oral conditions to return to the 
resting state before moving on to taking the next tablet. Participants recorded their own disintegration time using 
stop watches. The study involved no swallowing of the tablet and the participants were informed that all residue 
was to be removed from the oral cavity. Once all studies had been completed, results were collated. No patient 
demographic data was collected and there was also no patient identifiable data, as participants chose their own 
number/seat at the study.
Participant recruitment. A total of 35 healthy participants took part in the in vivo disintegration time study 
based on the selection criteria outlined in the Research Protocol, Patient Information Sheet and Patient Consent 
Form. Participants were required to commit up to 60 mins for the study. Participants were recruited from Aston 
University staff and were subject to inclusion and exclusion criteria to determine eligibility for the study. The vol-
unteers were sent participant information sheets and consent forms prior to the study and allowed to make their 
own informed decision on study participation.
Manufacture of tablets. A total of five different powder blends were prepared, with four blends compressed 
at two different compression forces and the fifth blend compressed using only one force (Table 1), giving a 
total of nine different batches of tablets. Tablets were composed of Pearlitol Flash (Roquette, Lestrem, France), 
Starch 1500 (Colorcon Inc., Harleysville, USA) and magnesium stearate (Fischer Scientific, Loughborough, UK) 
(Table 1). Excipient concentration and compression force was varied to obtain tablets of differing disintegration 
times, to allow for a wide range of times to be compared between the in vivo disintegration times and the times 
obtained for the in vitro methods.
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Data analysis. Each participant was required to take a total of six tablets, this comprised of two different tablet 
batches in triplicate. Each individual tablet batch was assessed 21 times; a participant took a particular tablet 
batch in triplicate, giving three readings, and a particular tablet batch was tested across seven different partici-
pants giving a total of 21 single readings per tablet batch. This approach was taken to gather not only inter-person 
variability but also intra-person variability, whilst also providing a very robust mean value. Data was presented 
as mean ± SD.
In Vitro tablet disintegration time assessment. The tablet formulations outlined in Table 1 were also tested in the 
standard USP test and Aston test. Each tablet batch was repeated in triplicate and data presented as mean ± SD.
Statistical analysis. One-way and two-way analysis of variance (ANOVA) followed by Tukey’s and Sidak’s 
multiple comparison post-hoc tests respectively, were performed in this study, using GraphPad Prism 6 software 
(California, USA). For statistical significance a p-value < 0.05 was used, and all data was presented as mean ± SD.
Results and Discussion
Validation of disintegration using newly developed aston disintegration tester. Although sev-
eral attempts have been made to design a test that is more specific to ODTs5–7,9,10,12–16,19–26, no test has reached 
approval specifically for ODT disintegration testing. The Aston test was conceptualised and developed as there 
is currently no validated test that broadly mimics the oral in vivo conditions encountered by an ODT during 
disintegration.
A systematic approach was taken to formulate ODTs with varying disintegration times by changing the com-
pression force from 75 to 300 MPa. Hardness and porosity values for all tablets are reported in Table 2. It was 
noted that as the compression force increased, tablet hardness and disintegration time of the ODTs increased, as 
expected. This was due to the particles in the compact interacting more closely and being bound tightly during 
the compression cycle, owing to the high content of MCC as a plastically deforming excipient27.
Disintegration times for the seven different formulations are shown in Table 2. The results showed that Aston 
test was sensitive to detect small differences in disintegration time (as little as 7 seconds). An important investiga-
tion in this study was to determine whether this test would be able to differentiate between an ODT and a stand-
ard immediate release/extended release tablet that would not usually disintegrate within the oral cavity. Table 2 
shows that the matrix tablet and the standard release paracetamol tablet had not disintegrated within the 180 s 
limit set for the Aston test. Upon visual evaluation, the matrix tablet was almost fully intact with a thin hydrated 
layer at the bottom of the tablet facing the media. Similarly, the paracetamol tablet remained intact, however a 
slightly larger proportion of the tablet had eroded and broken off the main structure.
Formulation Batch Pearlitol Flash (%) Starch 1500 (%) Magnesium Stearate (%) Compression Force (KN)
Powder Blend 1
B1
99.5 — 0.5
4
B2 9.5
Powder Blend 2
B3
89 10 1
9.5
B4 22
Powder Blend 3
B5
79 20 1
20
B5 46
Powder Blend 4
B7
49.5 49.5 1
26
B8 57
Powder Blend 5 B9 24.5 74.5 1 32
Table 1. Tablet formulation details for the 9 batches of tablets utilised in the in vivo disintegration study. Each 
powder blend, except powder blend 5, were compressed at two different compression forces to provide tablets of 
different disintegration/hardness profiles.
Formulation
Aston Test Disintegration 
Time (s)
USP Disintegration 
Time (s) Hardness (N)
Tensile strength 
(N/mm2) Porosity
75 MPa 22.51 ± 3.2 13.83 ± 0.25 58.67 ± 2.95 0.899 ± 0.076 0.399 ± 0.005
150 MPa 28.11 ± 2.5 14.47 ± 1.42 121.37 ± 7.60 2.120 ± 0.133 0.320 ± 0.010
225 MPa 35.27 ± 2.07 22.70 ± 2.00 154.87 ± 3.80 2.766 ± 0.062 0.314 ± 0.10
300 MPa 42.15 ± 2.07 28.60 ± 1.31 177.33 ± 6.12 3.267 ± 0.109 0.292 ± 0.011
Nurofen Meltlet 38.77 ± 3.96 15.80 ± 0.10 44.37 ± 2.41 0.447 ± 0.024 0.368 ± 0.004
Matrix 180.00 ± 0.00* 1800.00 ± 0.00* 173.70 ± 20.87 3.290 ± 0.575 0.300 ± 0.022
Paracetamol 180.00 ± 0.00* 97.60 ± 5.99 144.80 ± 10.20 1.875 ± 0.137 0.270 ± 0.013
Table 2. Tablet properties for all formulations tested in this study. All data is presented as mean ± SD, with data 
marked with an asterisk (*) showing the maximum time for the disintegration test, and therefore shows this 
tablet had not disintegrated within the stated time and was still left as a solid mass.
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Figure 3 illustrates the differences between the disintegration pathways of the evaluated ODTs and the 
non-disintegrating tablets (i.e. matrix-controlled release system and the standard release paracetamol tablets). It 
was deduced that all the ODTs followed a similar pathway, an initial small flat region, where water and humidity 
started to ingress into the tablet to break down the structure, as the tablet was not yet fully wet and still retained 
some mechanical strength; This was followed by a sharp increase in distance as the tablet was breaking down and 
falling apart from the main structure and away from the disintegration bed. This caused the probe to press further 
into the structure, given that there was very little resistance from the soft wet tablet. The final stage was when the 
probe had pushed through the ODT and on to the surface of the disintegration bed, whereby the plot came to a 
plateau as the probe reached its maximum force of 50 g. The plots also showed that there was a difference between 
the disintegration times for the ODTs manufactured at different compression forces (p < 0.05). The disintegration 
pathway for the ODTs showed that there was a difference in thickness of the tablets compressed at different forces, 
as the final distance for the tablets compressed at higher forces was smaller than those compressed at lower forces. 
This supported the theory that the test was sensitive enough to identify minor differences in disintegration time 
due to differences in compression force, mechanical strength and porosity.
However, for the extended release matrix tablet and the standard immediate release paracetamol tablet it was 
noted that the disintegration pathway was very different, with neither tablet undergoing significant disintegration. 
Both of these tablets are formulated to be swallowed whole and enter the GI tract, whereby the tablet would sub-
sequently disintegrate in a large volume of fluid over longer duration beyond 180 seconds. The paracetamol tablet 
was an immediate release dosage form, so it would disintegrate in the stomach in a relatively short time, whereas 
the matrix tablet was an extended release system that would slowly swell and erode layer by layer to provide 
sustained release of drug. The disintegration profile for both was similar at the start, where the water from under-
neath the tablet had come into contact with the tablet and the tablet interacted with the humidity in the chamber, 
providing a small increase in distance. However, after this initial movement, it was observed that the probe moved 
a very short distance (<0.5 mm). This was because the tablet remained rigid, as the media and humidity could not 
ingress into the tablet core and cause a breakdown of the structure, resulting in the probe applying its maximum 
set weight of 50 g throughout most of the test.
The comparison between ODTs and standard/extended release tablets was essential as the results indicated 
that the tester was able to clearly distinguish between different types of tablets. It also demonstrated that an ODT 
would disintegrate when tested but the other types of tablets remained intact, as they were manufactured to dis-
integrate or dissolve in larger volumes of fluid as opposed to the oral cavity.
comparison to the USp test. It was established that the newly developed disintegration tester was able to 
successfully determine different disintegration times and profiles between ODTs and standard release/extended 
release matrix tablets, whilst also providing different disintegration time between ODTs manufactured at different 
compression forces. The next important investigation was to analyse how the test compared to the standard USP 
disintegration test, especially for those ODTs manufactured in the laboratory. Figure 4 shows a comparative graph 
of the disintegration time for the Aston test and the USP test for all evaluated tablets.
The disintegration times for the four ODTs and the Nurofen Meltlets® appeared to be lower when tested in 
the USP test rather than the Aston test. This was expected as the conditions in the USP test, submerging the tablet 
in 800 ml of disintegration medium and oscillating it through the medium promoted rapid disintegration of the 
dosage form. This, alongside the mechanical agitation during the oscillations, resulted in rapid disintegration of 
the dosage form, compared to the conditions that would be encountered in the oral cavity6,10,13,26,28. In compari-
son, the Aston test consists of controlled flow of disintegration fluid whilst maintaining relative humidity in the 
disintegration chamber and was more representative of in vivo conditions compared to the conventional USP test.
It was observed that both the standard release paracetamol and matrix tablets experienced very little disin-
tegration during the Aston test, with results represented as the maximum set time of 180 s in Fig. 4. The matrix 
tablet also experienced very little disintegration during the standard USP test and remained intact at 30 mins. 
However, the standard release paracetamol tablet clearly disintegrated during the standard USP test at around 97 s. 
Figure 3. Disintegration profiles (distance vs time plots) of the seven formulations tested within the Aston test 
in this study, showing marked differences between disintegration pathways for ODTs and standard/controlled 
release formulations, and statistical significance observed (n = 8, p < 0.05).
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Upon visual analysis, and the analysis of the disintegration profile (Fig. 3) it was observed that the paracetamol 
tablet underwent very little disintegration during the Aston test, due to the small volume of disintegration fluid 
and controlled relative humidity.
Figure 5 shows the correlations for hardness, tensile strength, porosity and compression force against disinte-
gration time, for both the Aston test and the USP test. For this analysis, the standard release paracetamol tablets 
and matrix tablets were excluded as the comparison was ODT specific. All results indicated that the Aston test 
provided higher correlations, with the R2 (correlation factor) values for hardness, tensile strength, porosity and 
compression force being 0.92, 0.93, 0.77 and 0.99 respectively, compared to the lower respective values of 0.78, 
0.77, 0.56 and 0.92 obtained using the USP test. The correlation between hardness and tensile strength values 
(Fig. 5(A,B) respectively) was very high for the Aston test, with the USP test correlation falling far below this. 
Figure 4. A graph comparing disintegration times for the Aston disintegration test and the standard USP test, 
showing that for ODTs in the USP test provide lower disintegration times than the Aston test. Both values for 
the matrix tablet and the disintegration time for the paracetamol both reach the maximum time of 180 s in the 
Aston test and 1800 s in the USP test for the matrix tablet only; Values displayed on the graph have been set at 
180 s to represent the maximum. Data is presented as mean ± SD (n = 8 for Aston test and n = 3 for the USP 
test, p < 0.0001 for all data (except matrix tablet) when the Aston test is compared to the USP test, indicating 
that results are significantly different between the two tests). (Abbreviations: NM – Nurofen Meltlet; M – Matrix 
tablet; P – Standard release paracetamol).
Figure 5. (A) A graph comparing the correlation between hardness and disintegration time data for both the 
Aston test and the standard USP test, with results indicating a better correlation with the Aston test; (B) A graph 
comparing the correlation between tensile strength and disintegration time data for both the Aston test and the 
standard USP test, with results indicating a better correlation with the Aston test; (C) A graph comparing the 
correlation between porosity and disintegration time data for both the Aston test and the standard USP test, with 
results indicating a better correlation with the Aston test and (D) - A graph comparing the correlation between 
compression force of the tablet press and disintegration time data for both the Aston test and the standard USP 
test, with results indicating a better correlation with the Aston test.
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This showed that in terms of disintegration time, mechanical strength played an integral part, correlating almost 
linearly with disintegration time in the case of the Aston test under simulated in vivo conditions. In terms of the 
porosity of the tablet (Fig. 5C), the Aston test demonstrated a strong positive correlation, with an R2 value of 0.77, 
providing evidence that porosity also played a key role in the disintegration time of ODTs. On the other hand, 
the correlation for the USP test indicated a weaker correlation between the disintegration time and mechanical 
strength/porosity, suggesting that disintegration time didn’t strongly relate to these important properties of ODTs 
in the USP test.
Accordingly, based on the results gathered in this section, the Aston test proved to be a relevant method for 
measuring disintegration time for ODTs, as it provided more representative conditions to those encountered in 
vivo and also provided much stronger correlations to tablet properties compared to the standard USP test.
In vivo/In vitro correlation. The in vivo disintegration times for all batches were compared and correlated 
with results from the Aston test, as well as with the USP test (Fig. 6). The collection of 21 individual results per 
tablet for the in vivo study provided robust data for wide representation of disintegration times. To supplement 
this, results from seven participants were taken to calculate the mean for each tablet thereby ensuring inter- and 
intra-person variability was captured in data analyses. The tablets were manufactured varying compression forces 
to provide disintegration time profile from 10 to 150 s to enable correlation of results accepted by the EU regula-
tions (180 s)1 or the regulations recommended by the FDA (30 s)2.
Figure 6 shows the IVIVC for tablets spanning both the acceptable range for the EU and FDA regulation. 
Results indicated that the Aston test showed high linear correlation (R2 value 0.98) with the in vivo results. It was 
also observed that the Aston test was highly sensitive, whereby 1 second increase in in vivo disintegration time 
correlated with proportionate increase with Aston test. However, in comparison, the results obtained for the USP 
tester were not linear (with a curved dataset), indicating that the USP test was neither sensitive nor provided 
direct representation of the disintegration time for ODTs in vivo. Further analysis of the data, where ODTs with 
disintegration time meeting USP standards (<30 s) showed that the Aston test provided strong linear correlation, 
with an R2 value of 0.87, as opposed to USP test which had a very weak linear correlation of 0.61.
conclusion
The objective of this study was to develop and assess a novel disintegration test for ODTs which was constructed 
to simulate in vivo conditions the tablet would encounter during administration. Results from this study demon-
strated that the Aston test was sensitive and capable of distinguishing subtle differences in ODT disintegration 
time profile. A robust in vivo study design confirmed that the Aston test simulated the conditions (saliva volume, 
temperature, humidity) encountered in the oral cavity and provided a practical test representative of in vivo test 
data. The Aston test conclusively demonstrated that the novel method is accurate, precise, reproducible and linear 
thereby offering a pragmatic alternative to in vivo human subject testing. Standardisation of ODT disintegration 
test using the Aston test will ensure consistency in disintegration time data, which is a unique attribute for an 
ODT.
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